Drug Report History #2774
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-EN | Version v4-FR | |
|---|---|---|
| Language (Changed) | Updated to: English | Was: French |
| Date Updated (Changed) | Updated to: 2017-09-26 | Was: 2017-03-15 |
| Drug Identification Number | 02254638 | 02254638 |
| Brand name | PEGETRON | PEGETRON |
| Common or Proper name (Changed) | Updated to: peginterferon alfa-2b Powder for Solution / ribavirin Capsules | Was: PEGETRON® peginterferon alfa-2b Powder for Solution / PEGETRON® ribavirin Capsules |
| Company Name | MERCK CANADA INC | MERCK CANADA INC |
| Ingredients | PEGINTERFERON ALFA-2B RIBAVIRIN | PEGINTERFERON ALFA-2B RIBAVIRIN |
| Strength(s) | 120MCG 200MG | 120MCG 200MG |
| Dosage form(s) | CAPSULE POWDER FOR SOLUTION | CAPSULE POWDER FOR SOLUTION |
| Route of administration | ORAL SUBCUTANEOUS | ORAL SUBCUTANEOUS |
| Packaging size (Changed) | Updated to: 70 Capsules / 2 CLEARCLICK pens (2 dispositifs CLEARCLICK™) | Was: 70 Capsules / 2 CLEARCLICK pens |
| Additional packaging sizes | ||
| ATC code | L03AB | L03AB |
| ATC description | IMMUNOSTIMULANTS | IMMUNOSTIMULANTS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2017-06-30 | 2017-06-30 |
| Actual discontinuation date | ||
| Remaining supply date (Changed) | Updated to: 2017-09-30 | Was: 2017-06-30 |
| Discontinuation status | To be discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |